ImmunoPrecise Antibodies Statistics
Share Statistics
ImmunoPrecise Antibodies has 45.77M
shares outstanding. The number of shares has increased by 73.91%
in one year.
| Shares Outstanding | 45.77M |
| Shares Change (YoY) | 73.91% |
| Shares Change (QoQ) | 47.33% |
| Owned by Institutions (%) | 6.78% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 75,794 |
| FTD / Avg. Volume | 4.03% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.66 and the forward
PE ratio is -2.2.
ImmunoPrecise Antibodies's PEG ratio is
1.78.
| PE Ratio | -1.66 |
| Forward PE | -2.2 |
| PS Ratio | 1.84 |
| Forward PS | 0.4 |
| PB Ratio | 1.33 |
| P/FCF Ratio | -8.01 |
| PEG Ratio | 1.78 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for ImmunoPrecise Antibodies.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.41,
with a Debt / Equity ratio of 0.4.
| Current Ratio | 1.41 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.4 |
| Debt / EBITDA | -0.6 |
| Debt / FCF | -2.42 |
| Interest Coverage | -724.32 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $340,527.78 |
| Profits Per Employee | $-377,458.33 |
| Employee Count | 72 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 5.83 |
Taxes
| Income Tax | -1.53M |
| Effective Tax Rate | 5.32% |
Stock Price Statistics
The stock price has increased by -64.29% in the
last 52 weeks. The beta is 0.33, so ImmunoPrecise Antibodies's
price volatility has been higher than the market average.
| Beta | 0.33 |
| 52-Week Price Change | -64.29% |
| 50-Day Moving Average | 0.41 |
| 200-Day Moving Average | 0.52 |
| Relative Strength Index (RSI) | 54.47 |
| Average Volume (20 Days) | 1,879,472 |
Income Statement
In the last 12 months, ImmunoPrecise Antibodies had revenue of 24.52M
and earned -27.18M
in profits. Earnings per share was -1.06.
| Revenue | 24.52M |
| Gross Profit | 12.05M |
| Operating Income | -13.76M |
| Net Income | -27.18M |
| EBITDA | -22.95M |
| EBIT | -28.68M |
| Earnings Per Share (EPS) | -1.06 |
Full Income StatementBalance Sheet
The company has 3.46M in cash and 13.68M in
debt, giving a net cash position of -10.22M.
| Cash & Cash Equivalents | 3.46M |
| Total Debt | 13.68M |
| Net Cash | -10.22M |
| Retained Earnings | -100.27M |
| Total Assets | 45.53M |
| Working Capital | 11.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -4.25M
and capital expenditures -1.4M, giving a free cash flow of -5.64M.
| Operating Cash Flow | -4.25M |
| Capital Expenditures | -1.4M |
| Free Cash Flow | -5.64M |
| FCF Per Share | -0.22 |
Full Cash Flow StatementMargins
Gross margin is 49.16%, with operating and profit margins of -56.13% and -110.85%.
| Gross Margin | 49.16% |
| Operating Margin | -56.13% |
| Pretax Margin | -117.07% |
| Profit Margin | -110.85% |
| EBITDA Margin | -93.6% |
| EBIT Margin | -56.13% |
| FCF Margin | -23.02% |
